Table 4. Serum TNF-α and IL-6 levels in diabetic rats after treatment with NSO, antidiabetic drugs, combination therapy and I-OMeAG538.

Group	TNF-α (pg/ml)	IL-6 (pg/ml)
Control	16.60 ± 0.24#	100.00 ± 2.11#
D	134.00 ± 2.40*	610.00 ± 3.00*
DMSO	75.90 ± 1.90*	402.00 ± 5.01*#
NSO	14.00 ± 0.32#	85.50 ± 3.10*#
MT	16.10 ± 0.93#	100.10 ± 3.02#
NSO-MT	15.70 ± 0.47#	110.50 ± 3.00#
GI	23.90 ± 1.29*#	182.50 ± 3.00*#
NSO-GI	19.00 ± 0.27*#	162.30 ± 1.90*#
D-NSO	17.01 ± 0.52#	120.70 ± 2.91#
D-MT	24.43 ± 0.83*#	188.10 ± 3.94*#
D-GI	30.70 ± 1.22*#	196.50 ± 3.01*#
D-NSO-MT	18.90 ± 0.24*#	122.50 ±2.63#
D-NSO-GI	22.60 ± 0.22*#	250.40 ± 3.99*#
IOMe	100.50 ± 2.49*#	450.50 ± 3.55*#
IOMe-NSO	45.80 ± 1.13*#	198.50 ± 2.03*#
D-IOMe	127.90 ± 2.84*	650.30 ± 5.67*
D-IOMe-NSO	57.20 ± 1.25*#	200.50 ± 3.69*#

Values are expressed as mean± SE (n = 8). Significance:

*p<0.05 (compared to control) and

^#p<0.05 (compared to diabetics).